Search Grants — Free, No Account Required

New York Power Authority (NYPA)

As part of NYPA's funding of its workforce training incentives is the renewable energy field, NYPA is supporting the WVI Dolphin Foundation?s Leadership Mentor Program that provides clean energy career knowledge and opportunities for underserved high school students.

NCATS - National Center for Advancing Translational Sciences

The Yale Center for Clinical Investigation (YCCI) was created in 2005 to advance Yale's clinical research mission. One year later, YCCI became the home of the Yale CTSA. At YCCIs inception, Yale was a national leader in T0-T2 translational research, basic/translational science training, and it supported distinctive translational science T3-T4 fellowship programs such as the Robert Wood Johnson Clinical Scholars Program. Since then, the CTSA has had a transformative impact linking all components of the Yale community in T1-T4 research, providing the central infrastructure for the effective conduct of ethical, innovative, rigorous, and reproducible research, and in training the next generation of research leaders. By any metric of scale, breadth, quality, and impact, both the CTSA's research enterprise and its educational mission have been enormously successful for Yale. This renewal application does not simply seek to maintain excellence, but to enable YCCI to drive the continued transformation of the Yale T1-T4 translational research mission and its predoctoral and postdoctoral training mission and to promote collaboration across CTSA hubs. First, it will support informatics and computational advances that drive the emergence of a learning health system. In so doing, it will draw on the Yale New Haven Health System, a six-hospital 2,681-bed consortium that provides more than 2.4 million outpatient visits annually from patients from upper Westchester county, throughout Connecticut, and southern Rhode Island. It will also prepare young scientists to draw on this infrastructure to conduct research that influences the future of healthcare. Second, it will support technological and scientific advances in areas that will support the emergence of personalized healthcare, including multi-omics and imaging. YCCI will provide pilot grant support and training to foster the development of research careers and research teams that can deepen our insights into pathophysiology and build toward personalized treatments. Third, it will engage a broader and multidisciplinary group of faculty, trainees, and community representatives to collaborate to improve health outcomes that constitute a major burden on patients, their families, and on public health. To support this mission, YCCI will also foster the development of careers in community-based research from a multidisciplinary group of young investigators and enhance the overall clinical research workforce.

FIC - John E. Fogarty International Center for Advanced Study in the Health Sciences

Project Abstract Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) affect 51 million people worldwide, a prevalence expected to triple by 2050. Two-thirds of those with AD/ADRD live in low- and middle- income countries (LMICs) where the greatest growth in AD/ADRD prevalence is expected, but where services to diagnose and manage this condition are scarce and data regarding dementia burden are limited. Although the Lancet Commission on Dementia, Prevention, Intervention, and Care has identified 14 modifiable risk factors that contribute to 45% of AD/ADRD cases worldwide, there are limited data regarding the prevalence and role of these modifiable risk factors in LMICs. Thus, interventions targeting these factors may have limited impact on AD/ADRD risk in LMIC settings. This proposal’s overall objective is to assess the prevalence rate of AD/ADRD and associated risk factors among adults age ≥55 years in urban and rural Zambia, a LMIC in sub- Saharan Africa. Based on our pilot work, we hypothesize that the prevalence rate of AD/ADRD among adults age ≥55 years will be approximately 9.5% and prevalence of associated risk factors will differ between urban and rural participants. These hypotheses will be tested through a population-based study of adults age ≥55 years in the urban Lusaka and rural Mazabuka Districts of Zambia. AD/ADRD prevalence will be assessed using formal neuropsychological testing, participant, and informant report according to DSM-V criteria. Additional validated questionnaires, a physical examination, and laboratory investigations will assess AD/ADRD risk factors. This project will also build and expand the neuropsychiatric expertise and workforce necessary to conduct prospective AD/ADRD research by providing training and AD/ADRD research experience for a Zambian neuropsychologist, neuropsychologists-in-training, and a cohort of community health workers. The proposed research is highly innovative because it examines AD/ADRD prevalence in a population with limited existing data and expected growth in rates of AD/ADRD and associated risk factors. Knowledge gained from this work will determine (1) the prevalence of AD/ADRD and (2) the prevalence of modifiable risk factors which have the greatest impact on AD/ADRD prevalence in this rapidly aging population. This project will have a significant impact by expanding the capacity for AD/ADRD studies in Zambia and will lay the groundwork for the conduct of future longitudinal studies and trials assessing low-cost interventions to reduce AD/ADRD prevalence and improve patient care.